Elucidating Heterocyclic Chemistry in Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Elucidating Heterocyclic Chemistry in Pharmaceuticals
Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.


Pharmaceutical Technology
Volume 37, Issue 6, pp. 44-46


Patricia Van Arnum
Heterocyclic compounds play an important role in medicinal chemistry and drug synthesis. Like any important functional class of compounds, developments that facilitate their production or elucidate their reaction mechanisms are significant for process chemists in the pharmaceutical industry. In two separate developments, researchers at The Scripps Research Institute (TSRI) in La Jolla, California recently reported on the use of zinc sulfinates as reagents for the direct chemical functionalization of nitrogen-based heterocycles and on reaction-tracking tools to better elucidate copper-catalyzed reactions in making triazoles.

A toolkit for synthesizing heterocycles

In the first development, scientists at TSRI developed a set of chemical tools to simplify the synthesis of nitrogen-based heterocycles through more time- and cost-efficient chemical modifications of these compounds. In their work, the researchers pointed out that although advances in transition-metal-mediated cross-coupling have simplified the synthesis of such heterocycles, the carbon–hydrogen functionalization of medicinally important heterocycles that does not rely on prefunctionalized starting materials was an area requiring further research (1). Although the properties of heterocycles, such as their aqueous solubility and their ability to act as ligands, are desirable for biological applications, these properties also make such heterocycles challenging as substrates for direct chemical functionalization (1). To address that problem, the researchers used zinc sulfinate salts to transfer alkyl radicals to heterocycles, thereby allowing for the mild (i.e., moderate temperature, 50 C or less), direct, and simple formation of carbon–carbon bonds while reacting in a complementary fashion to other carbon–hydrogen functionalization methods (i.e., Minisci, borono-Minisci, electrophilic aromatic substitution, transition-metal-mediated carbon–hydrogen insertion, and carbon–hydrogen deprotonation) (1). The researchers prepared a toolkit of these reagents and studied their reactivity across a range of heterocycles (natural products, drugs, and building blocks) without recourse to protecting-group chemistry. The reagents could be used in tandem in a single pot in the presence of water and air (1).


LAGUNA DESIGN/GETTY IMAGES
"Feedback from companies that have started to use this toolkit indicates that it solves a real problem for them by boosting their chemists' productivity and by expanding the realm of compounds that they can feasibly generate," said Phil S. Baran, PhD, a professor in the Department of Chemistry and a member of the Skaggs Institute for Chemical Biology at TSRI who led the study, in a Nov. 28, 2012 TSRI press release. The resistance of nitrogen heterocycles to modification by traditional techniques has slowed drug discovery and has put potential modifications out of reach, notes TSRI.

The genesis behind the toolkit began with the goal for a more a simplified approach. "The ideal for discovery chemists would be a method that works in water, in an open flask, [and] with procedures that are simple enough to be automated," said Baran. His group's previous work in synthesizing a natural product heterocycle, palau'amine, a toxin made by sea sponges in the Western Pacific that has shown anticancer, antibacterial and antifungal pharmaceutical promise, was a helpful beginning.

"As we developed an understanding of how that compound reacts, we recognized that it might help us solve this larger problem that discovery chemists face," said Baran in the release. In that synthesis, palau'amine was made by a route featuring highly chemoselective transformations, cascade reactions, and a transannular cyclization to produce the trans-5,5 ring junction (2) and led the researchers to examine reagents that would modify heterocycles directly.

Although direct methods exist, they often require extreme temperatures as well as expensive and hazardous reagents. During 2010 and 2011, Baran's laboratory experimented with several comparatively safe chemical reagents that work in mild conditions to make commonly desired heterocycle modifications, such as the addition of a difluoromethyl group, according to the TSRI 2012 release. One of these new reagents, a zinc dialkylsulfinate salt (DFMS), which was designed to transfer the difluoromethyl group, turned out to work particularly well. "We quickly realized that we might be able to make related zinc sulfinate salts that would attach other functional groups to heterocycles," Baran said.

In their recent work, Baran and his team developed an initial toolkit consisting of 10 of these zinc-based salts, each of which attaches a different functional group to a heterocycle framework. "We selected these groups because they are commonly used by medicinal chemists," said Fionn O'Hara, PhD, a postdoctoral researcher in the Baran laboratory and a co-author of the recent study (1). In many cases, these reagents can be used to sequentially make more than one modification to a starting compound. The groups that can be attached with the new reagents include trifluoromethyl, difluoromethyl, trifluoroethyl, monofluoromethyl, isopropyl and triethylene glycol monomethyl ether.

To show the ability of the reagents to work in biological media, Baran's team used the reagents to difluoromethylate or trifluoromethylate heterocycles in a solution of cell lysate as well as to serve as a buffer medium (i.e., tris), which is commonly used in laboratory-dish tests.

Baran's laboratory collaborated with scientists from Pfizer. "They provided insight into the types of compounds that would be valuable, assistance with optimization, and, most importantly, testing of the chemistry in their drug-discovery laboratories, where it is meant to be used," Baran said.

The first of the zinc sulfinate salts, DFMS, also known as Baran difluoromethylation reagent, is being manufactured in bulk and marketed by chemical suppliers, according to the TSRI release. Baran is working to expand his initial toolkit to provide more heterocycle-modifying choices.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here